Clinical Trial Update: Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating propranolol in combination with tislelizumab and gemcitabine/cisplatin as neoadjuvant therapy for bladder urothelial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Propranolol (propranolol)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Bladder Urothelial Carcinoma, Lymph Node Metastasis | Phase 1 | Status: ENROLLING_BY_INVITATION